MBRX News and Press, Moleculin Biotech Inc. From 07/21/20

Moleculin Biotech (NASDAQ: MBRX ) rises  ~35%  PM in reaction to  independent laboratory testing that confirms antiviral activity of WP1122 against coronavirus. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Immuron (NASDAQ: IMRN ) +114%  on potential of hyperimmune bovine antibodies in COVID-19. More news on: Immuron Limited, Midatech Pharma plc, New Age Beverages Corporation, , , Stocks on the move Read more ...

HOUSTON , July 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of inde...

Moleculin Biotech (NASDAQ: MBRX )   surges 44%  premarket after signing an agreement with Sterling Pharma USA for US production of WP1122 to support its expanded development efforts in preparation for submitting the FDA request for IND status for WP1122 for the potential treatme...

HOUSTON , July 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has entered into an...

Moleculin Biotech (NASDAQ: MBRX ) announces an update on its clinical development plan for Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...

HOUSTON , July 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced an update on its clinical de...

HOUSTON , July 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article publ...

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive ...

Moleculin Biotech (NASDAQ: MBRX ) announces data from a presentation entitled, "Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors." More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...